MNG281
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.692
- INFLAMMATORY_RESPONSE+0.568
- IL6_JAK_STAT3_SIGNALING+0.563
- ALLOGRAFT_REJECTION+0.483
- HYPOXIA+0.469
- ANGIOGENESIS+0.452
- TGF_BETA_SIGNALING+0.437
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.436
- IL2_STAT5_SIGNALING+0.435
- MYOGENESIS+0.434
Top 10 suppressed
- DNA_REPAIR-0.252
- E2F_TARGETS-0.229
- PEROXISOME-0.215
- BILE_ACID_METABOLISM-0.184
- FATTY_ACID_METABOLISM-0.088
- WNT_BETA_CATENIN_SIGNALING-0.029
- SPERMATOGENESIS+0.013
- OXIDATIVE_PHOSPHORYLATION+0.026
- MYC_TARGETS_V1+0.062
- APICAL_SURFACE+0.097
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s_150324_4b | EPN | Posterior Fossa EPN | 0.927 |
| 2 | SRR26320076 | — | — | 0.926 |
| 3 | MNG918 | — | — | 0.926 |
| 4 | MNG639 | — | — | 0.924 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.914 |
| 6 | BS_4T0HPZDC | EPN | Posterior Fossa EPN | 0.913 |
| 7 | BS_EN2VK7NY | low-grade glioma | — | 0.910 |
| 8 | TCGA-CN-6020-01A-11R-1686-07 | — | — | 0.904 |
| 9 | MNG553 | — | — | 0.902 |
| 10 | MNG120 | — | — | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.692 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.568 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.563 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.483 | Idelalisib | — uncovered |
| HYPOXIA | 0.469 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.452 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.437 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.436 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.435 | Idelalisib | — uncovered |
| MYOGENESIS | 0.434 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.419 | Inavolisib | — uncovered |
| APOPTOSIS | 0.411 | Idelalisib | — uncovered |
| COMPLEMENT | 0.363 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.328 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.316 | Idelalisib | — uncovered |
| COAGULATION | 0.303 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.291 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.278 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.266 | Idelalisib | — uncovered |